

David S Rickman

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/1158707/publications.pdf>

Version: 2024-02-01

29
papers

3,260
citations

394421

19
h-index

552781

26
g-index

29
all docs

29
docs citations

29
times ranked

5292
citing authors

#	ARTICLE	IF	CITATIONS
1	Molecular Characterization of Neuroendocrine Prostate Cancer and Identification of New Drug Targets. <i>Cancer Discovery</i> , 2011, 1, 487-495.	9.4	725
2	N-Myc Induces an EZH2-Mediated Transcriptional Program Driving Neuroendocrine Prostate Cancer. <i>Cancer Cell</i> , 2016, 30, 563-577.	16.8	394
3	Aggressive Variants of Castration-Resistant Prostate Cancer. <i>Clinical Cancer Research</i> , 2014, 20, 2846-2850.	7.0	339
4	Whole-Exome Sequencing of Metastatic Cancer and Biomarkers of Treatment Response. <i>JAMA Oncology</i> , 2015, 1, 466.	7.1	264
5	Biology and evolution of poorly differentiated neuroendocrine tumors. <i>Nature Medicine</i> , 2017, 23, 664-673.	30.7	192
6	SLC45A3-ELK4 Is a Novel and Frequent Erythroblast Transformation-Specific Fusion Transcript in Prostate Cancer. <i>Cancer Research</i> , 2009, 69, 2734-2738.	0.9	181
7	A Phase II Trial of the Aurora Kinase A Inhibitor Alisertib for Patients with Castration-resistant and Neuroendocrine Prostate Cancer: Efficacy and Biomarkers. <i>Clinical Cancer Research</i> , 2019, 25, 43-51.	7.0	177
8	The Expanding World of N-MYC-Driven Tumors. <i>Cancer Discovery</i> , 2018, 8, 150-163.	9.4	170
9	Oncogene-mediated alterations in chromatin conformation. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2012, 109, 9083-9088.	7.1	142
10	N-Myc-mediated epigenetic reprogramming drives lineage plasticity in advanced prostate cancer. <i>Journal of Clinical Investigation</i> , 2019, 129, 3924-3940.	8.2	115
11	Delta-like protein 3 expression and therapeutic targeting in neuroendocrine prostate cancer. <i>Science Translational Medicine</i> , 2019, 11, .	12.4	105
12	ERG induces taxane resistance in castration-resistant prostate cancer. <i>Nature Communications</i> , 2014, 5, 5548.	12.8	96
13	Association with Aurora-A Controls N-MYC-Dependent Promoter Escape and Pause Release of RNA Polymerase II during the Cell Cycle. <i>Cell Reports</i> , 2017, 21, 3483-3497.	6.4	71
14	ERG Cooperates with Androgen Receptor in Regulating Trefoil Factor 3 in Prostate Cancer Disease Progression. <i>Neoplasia</i> , 2010, 12, 1031-IN22.	5.3	51
15	Temporal evolution of cellular heterogeneity during the progression to advanced AR-negative prostate cancer. <i>Nature Communications</i> , 2021, 12, 3372.	12.8	45
16	Identification of novel prostate cancer drivers using RegNetDriver: a framework for integration of genetic and epigenetic alterations with tissue-specific regulatory network. <i>Genome Biology</i> , 2017, 18, 141.	8.8	31
17	A Computational Drug Repositioning Approach for Targeting Oncogenic Transcription Factors. <i>Cell Reports</i> , 2016, 15, 2348-2356.	6.4	29
18	Integrative Molecular Analysis of Patients With Advanced and Metastatic Cancer. <i>JCO Precision Oncology</i> , 2019, 3, 1-12.	3.0	24

#	ARTICLE	IF	CITATIONS
19	Extracellular Matrix in Synthetic Hydrogel-Based Prostate Cancer Organoids Regulate Therapeutic Response to EZH2 and DRD2 Inhibitors. <i>Advanced Materials</i> , 2022, 34, e2100096.	21.0	24
20	Characterization of the ERG-regulated Kinome in Prostate Cancer Identifies TNIK as a Potential Therapeutic Target. <i>Neoplasia</i> , 2019, 21, 389-400.	5.3	20
21	Targeting the epichaperome as an effective precision medicine approach in a novel PML-SYK fusion acute myeloid leukemia. <i>Npj Precision Oncology</i> , 2021, 5, 44.	5.4	20
22	RNA Splicing Factors SRRM3 and SRRM4 Distinguish Molecular Phenotypes of Castration-Resistant Neuroendocrine Prostate Cancer. <i>Cancer Research</i> , 2021, 81, 4736-4750.	0.9	18
23	Oncogenic transcription factors as master regulators of chromatin topology. <i>Cell Cycle</i> , 2012, 11, 3380-3383.	2.6	14
24	AR-V7 exhibits non-canonical mechanisms of nuclear import and chromatin engagement in castrate-resistant prostate cancer. <i>ELife</i> , 0, 11, .	6.0	10
25	Precision medicine program for whole-exome sequencing (WES) provides new insight on platinum sensitivity in advanced prostate cancer (PCa).. <i>Journal of Clinical Oncology</i> , 2015, 33, 158-158.	1.6	1
26	Targeting the Epichaperome As an Effective Precision Medicine Approach in a Novel PML-SYK Fusion Acute Myeloid Leukemia. <i>Blood</i> , 2018, 132, 1435-1435.	1.4	1
27	Immunogenomic landscape of neuroendocrine prostate cancer (NEPC).. <i>Journal of Clinical Oncology</i> , 2019, 37, 224-224.	1.6	1
28	Abstract PR08: The N-Myc transcriptional program driving the neuroendocrine prostate cancer phenotype. , 2015, , .		0
29	Extracellular Matrix in Synthetic Hydrogel-Based Prostate Cancer Organoids Regulate Therapeutic Response to EZH2 and DRD2 Inhibitors (<i>Adv. Mater.</i> 2/2022). <i>Advanced Materials</i> , 2022, 34, .	21.0	0